Clinical Scorecard: Clinical Outcomes After One Year of MR-Guided Stereotactic Body Radiation Therapy with Rectal Spacer in Patients with Localized Prostate Cancer

At a Glance

Key Highlights

• MRgSBRT offers superior soft tissue contrast and daily adaptive planning to improve oncological outcomes and quality of life.
• Rectal spacers (PEG-based hydrogel or hyaluronic acid) effectively increase prostate-rectum distance, reducing rectal toxicity risk during SBRT.
• Preliminary data show MRgSBRT with rectal spacers is feasible, safe, and associated with lower acute genitourinary and gastrointestinal toxicities.

Guideline-Based Recommendations

Diagnosis

• Confirm localized prostate adenocarcinoma with MRI and/or PSMA PET to exclude nodal or distant metastasis.
• Assess patient eligibility including ECOG performance status < 2 and absence of contraindications such as inflammatory bowel disease.

Management

• Consider MRgSBRT with 36.25–40 Gy in 5 fractions, with optional dose boost to dominant intraprostatic lesions.
• Insert rectal spacer at least 10 days prior to MRgSBRT to reduce rectal radiation dose and toxicity.
• Use androgen-deprivation therapy according to risk stratification and physician discretion.

Monitoring & Follow-up

• Perform simulation CT and MRI scans with full bladder and empty rectum prior to treatment planning.
• Use daily online MRI for adaptive planning and real-time motion management during MRgSBRT.
• Monitor patient-reported outcomes and clinician-reported toxicities up to at least one year post-treatment.

Risks

• Potential rectal toxicity due to high radiation dose per fraction in SBRT without spacer use.
• Contraindications include prior pelvic irradiation, MRI contraindications, and inflammatory bowel disease.
• Spacer placement risks include procedural complications, requiring ultrasound guidance and anesthesia.

Patient & Prescribing Data

Localized prostate cancer patients eligible for MRgSBRT and rectal spacer insertion

Rectal spacers improve dosimetric profiles and reduce acute GU and GI toxicities; MRgSBRT allows adaptive treatment with superior imaging guidance.

Clinical Best Practices

• Discuss rectal spacer option with all eligible localized prostate cancer patients planned for MRgSBRT.
• Perform spacer insertion under ultrasound guidance with local or general anesthesia at least 10 days before simulation.
• Use a rectal balloon during simulation and treatment to maintain rectal position and volume consistency.
• Prescribe ADT based on risk stratification and clinical guidelines, tailoring duration accordingly.
• Leverage daily MRI for adaptive planning to address anatomical changes and spacer positioning.

References

• External beam radiation therapy standards for localized prostate cancer
• Hypofractionated radiation therapy in prostate cancer
• Stereotactic body radiation therapy (SBRT) feasibility and safety
• Rectal spacer development and clinical use
• MR-guided SBRT and MIRAGE trial results
• Dosimetric advantages of rectal hydrogel spacers
• Patient-reported outcomes with hydrogel spacers in MRgSBRT